Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Generic drugs maker Noumed Pharma announces new Australia plant

By Sean Whooley | March 6, 2024

Noumed PharmaceuticalsNoumed Pharmaceuticals says it started construction on a $100 million purpose-built facility in South Australia’s northern suburbs.

According to a news release. the company expects this facility to become the most modern of its kind in Australia. The state-of-the-art pharmaceutical manufacturing plant enhances the country’s sovereign supply into the pharmacy and health networks. Noumed plans to manufacture certain over-the-counter pharmaceuticals on domestic soil, rather htan overseas.

During the first stage, Noumed plans to manufacture liquid-based products like cough mixtures, children’s suspensions and nasal perforations. Other products include creams, while the company plans to pack solid dose tablets. The second stage is set to enable the company to manufacture those solid dose tablets as well.

Noumed says it placed the construction on a 43,000-square meter site with a floor area of 26,000 square meters. It expects the project to create 250 jobs in South Australia during construction before housing more than 180 employees when local production begins in 2026. The Australian government pledged up to $20 million in funding.

Noumed’s Managing Director, Mark Thulborne, said: “By coming back into Australia, current and future clients can have the comfort that many of their products are being made in South Australia. This means a shorter lead time to their shelves and a supplier that can react quickly to their individual needs. I think this demonstrates our long-term commitment to the customers we serve, and it will give them an unmatched competitive advantage.”

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Tell Us What You Think! Cancel reply

Related Articles Read More >

Eli Lilly Huntsville Alabama Facility rendering (1)
Eli Lilly to build new $6B API manufacturing facility in Alabama
Thermo Fisher Scientific
Thermo Fisher expands investment in Asia bioprocessing for biopharma production
AstraZeneca
AstraZeneca to invest $2B in Maryland, support 2,600 jobs
This is the logo of Novartis.
Novartis opens new manufacturing plant in California
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE